INTRODUCTION

Obesity is one of the greatest public health challenges of the 21st century. In 2008, the World Health Organisation (WHO) reported that 1.5 billion adults globally (age ≥ 20 years) were overweight and at least 500 million adults were obese. In addition, WHO forecasted that approximately 2.3 billion adults will be overweight and more than 700 million adults will be obese by 2015 (WHO, 2010). Meanwhile, more than 220 million people worldwide have diabetes (WHO, 2011). Gut hormones release has been shown to play a role in the prevalence of obesity through food intake reduction and appetite satisfaction. Release of gut hormones could be regulated by the consumption of dietary fats. Moreover, gut hormones such as glucagon like-peptide 1 and glucagon insulinotropic dependent polypeptide have been implicated in the treatment of patients with diabetes.

GUT HORMONES

Gut hormones are satiety signals that are released from the gastrointestinal (GI) tract which modulates the activity of appetite centres within the brain. These signals play a fundamental role in regulating food intake and satiety as well as in energy balance. Gut hormones also play an important physiological role in postprandial satiety (fullness after consumption of a meal) and hence, regulate meal initiation and termination. Figure 1 shows various gut hormones being secreted from different organs in the body.

Gut hormones such as glucose dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), cholecystokinin (CCK) and peptide YY (PYY) are released from the small intestine while ghrelin is secreted from the stomach (Figure 1). PYY acts on hypothalamus of the brain to send signals that will suppress appetite while CCK sends a satiety signal that will reduce food intake. Meanwhile, secretion of ghrelin will stimulate food intake. Table 1 shows the effects of various gut hormones on food consumption as well as in postprandial satiety. For example, when CCK, GLP-1, GIP or PYY are secreted, it will reduce food consumption and appetite, thus increasing fullness. Therefore, secretion of these gut hormones when dietary fats are consumed is directly involved in preventing the development of obesity, satiety and food intake.

CURRENT FINDINGS OF DIETARY FATS AND POSSIBLE ROLE OF TRIACYLGLYCERIDES STRUCTURE ON GUT HORMONES SECRETION

Entry of dietary fat into the small intestine induces the release of gut peptides upon interaction between the gut wall and nutrients. The presence of fat in the small intestine modulates the secretion of gut hormones such as GIP, GLP-1, CCK, PYY and ghrelin, all of which have been implicated in the regula-
Effects of Dietary Fats on Gut Hormones Release and Satiety

The degree of fat saturation affects hunger and food intake as well as the secretion of gut hormones. This was shown from studies carried out by several researchers related to the effect of fat saturation on hunger and food intake. Ingestion of unsaturated fats induced a greater reduction in food intake as compared to saturated fats.

Maljaars et al. (2009) reported that shea butter with C18:0 did not reduce hunger or fullness whereas unsaturated fats of canola oil and safflower oil did reduce hunger and increase fullness. Moreover, there was no significant difference in food intake between treatments (shea butter; C18:0, canola oil; C18:1; safflower oil; C18:2) given to human volunteers (Maljaars et al., 2009). Macintosh et al. (2003) reported that the degree of fat saturation did not alter satiety responses.

On secretion of gut hormones, Maljaars et al. (2009) reported that polyunsaturated fatty acids (PUFA) from canola oil with C18:1 and safflower oil with C18:2 have shown that it increased the secretion of plasma CCK while there was no significant effect on secretion on gut hormones shown by saturated fats such as shea butter with C18:0. Furthermore, release of GLP-1 has been shown to increase after a MUFA-rich (olive oil) meal compared with a SFA-rich (coconut oil) meal (Thomsen et al., 1999; 2003; Rocca et al., 2001). Secretion of gut hormones after a SFA-rich meal was secreted to a lesser extent as compared to MUFA and PUFA-rich meal. Therefore, it would be interesting to explore whether palm oil will induce an effect on gut hormone secretion.

Palm oil is mainly used as cooking oil in Southeast Asia countries while its fractions such as palm stearin and palm mid fraction are used in confectionary products

<table>
<thead>
<tr>
<th>Gut hormones</th>
<th>Food consumption</th>
<th>Satiety (fullness)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholecystokinin</td>
<td>Reduce</td>
<td>Increase</td>
</tr>
<tr>
<td>Glucagon-like peptide 1</td>
<td>Reduce</td>
<td>Increase</td>
</tr>
<tr>
<td>Peptide YY</td>
<td>Reduce</td>
<td>Increase</td>
</tr>
<tr>
<td>Glucose dependent insulinotropic polypeptide</td>
<td>Reduce</td>
<td>Increase</td>
</tr>
<tr>
<td>Ghrelin</td>
<td>Increase</td>
<td>Reduce</td>
</tr>
</tbody>
</table>

Source: adapted from Maljaars et al. (2007).
such as instant noodles, bread and cookies as well as chocolates. Interestingly, palm oil has a unique positional distribution in its triacylglycerides (TAG) molecule as shown in Figure 2. About 89%-93% palmitic acid occupy the sn-1 and sn-3 positions of the palm triacylglyceride molecule, while the sn-2 position is occupied by 60%-70% of the monounsaturated oleic acid and 7%-11% of palmitic acid. It is hypothesised that the oleic acid at the sn-2 position will be absorbed into the body and does not alter the blood lipid profile.

Previous studies as described above have shown that the degree of saturation of fat affects satiety and food intake (Thomsen et al., 1999; 2003; Rocca et al., 2001; Thomsen et al., 2003; Maljaars et al., 2009). However, these studies were not designed to investigate the effects of the positional distribution of TAG (especially in palm oil) on the release of gut hormones as well as in satiety and food intake. Furthermore, it will be interesting to find out whether the degree of saturation of different test oils with different types of fatty acid at the sn-1 and sn-3 positions will affects gut hormones secretion and food intake.

**IMPORTANCE OF GUT HORMONES SECRETION IN THE INCIDENCE OF OBESITY AND DIABETES**

Gut hormones secretion from various forms of dietary fats has resulted in a great interest on the effects of gut hormones release on food intake, satiety as well as performing as anti-obesity ‘tool’. A dietary fat intake will give a greater postprandial satiety (act of fullness), which in turn can facilitate weight loss. This suggests that the subject will get full when he is given an intake of dietary fat and when the subject will be eating less, and thus committing him to weight loss.

GLP-1 has been shown in obese subjects that it was effective in reducing appetite and food intake as well as calorie intake in humans. The GLP-1 interacts with gastric or duodenal satiety signals (act of fullness), which in turn can facilitate weight loss. This suggests that the subject will get full when he is given an intake of dietary fat and when the subject will be eating less, and thus committing him to weight loss.

Studies have shown that gut hormones secretion induces a lower food intake and increases satiety, and hence this may reduce the percentage of obesity incidence occurrence. Therefore, this has prompted a research to be carried out to study the effects of sn-1 and sn-3 palmitic or stearic acid-rich fats on the release of gut hormones which may have a link to anti-obesity incidence.

Both GIP and GLP-1 hormones increase the amount of insulin released from the β cells of pancreas. The secretion of insulin has been implicated in the treatment of type 2 diabetes mellitus, a global disease phenomenon that affects 90% of people and is largely the result of excess body weight and lack of physical activity (WHO, 2009). Insulin facilitates the uptake of glucose by muscle tissue and the liver while simultaneously suppressing glucagon secretion, leading to reduced production of glucose (Drucker, 2007).

Studies have shown that gut hormones secretion induces a lower food intake and increases satiety, and hence this may reduce the percentage of obesity incidence occurrence. Therefore, this has prompted a research to be carried out to study the effects of sn-1 and sn-3 palmitic or stearic acid-rich fats on the release of gut hormones which may have a link to anti-obesity incidence.
CONCLUSION

GI tract plays a key role in satiety through various gut hormones being secreted in response to dietary intake of food. Gut hormones established from the consumption of dietary fats consisting of fatty acids have brought upon an additional answer in tackling the question of the 21st century, obesity. It is inevitable that gut hormones plays a major role in the regulation of body weight and represent therapeutic targets for the future treatment of obesity, thus it has been an important area to be explored for palm oil. Further scientific research on palm oil on the effects of gut hormones will thus enhance the value of palm oil.

REFERENCES


